Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes

详细信息    查看全文

• 作者：Megan Fracol MD ; Jashodeep Datta MD ; Lea Lowenfeld MD…
• 刊名：Annals of Surgical Oncology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：24
• 期：2
• 页码：407-417
• 全文大小：
• 刊物主题：Surgical Oncology; Oncology; Surgery;
• 出版者：Springer International Publishing
• ISSN：1534-4681
• 卷排序：24

文摘

BackgroundWe previously demonstrated a progressive loss of the anti-human epidermal growth factor receptor 2 (HER2) CD4+ T-helper type 1 (Th1) response during HER2pos breast tumorigenesis. This loss is associated with residual disease following neoadjuvant therapy and increased risk of recurrence. In this study, we assessed the fate of anti-HER3 Th1 immunity during breast tumorigenesis.